More people will have access to a new treatment for Alzheimer’s — thanks to a UW study
People between the ages of 55 to 80 who are at high risk for Alzheimer’s will be eligible for the study — and will get no-cost access to Lecanemab — which has an annual estimated cost of more than $26,000., is the first traditionally-approved treatment that addresses the underlying biology of Alzheimer’s and changes the course of the disease in a meaningful way for people in the early stages.
Lecanemab slowed participants’ cognitive and functional decline by 27% over the course of 18 months during Clarity AD trials, Rosenbloom said, adding that the drug’s longer-term effectiveness is not well understood.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Pollution from Canada’s wildfires was similar to breathing secondhand smoke indoors, study showsResearchers from Rutgers University hope to better understand wildfire smoke and its potential health consequences.
Les mer »
Kids and guns: Study reveals how to reduce the risk of kids playing with found firearm'Guns are one of those topics parents may be worried to discuss, with the thought, If we discuss it, will it make them more curious about guns?' Hillary Ammon, a clinical psychologist at the Center for Anxiety and Women's Emotional Wellness said.
Les mer »
Espresso could lower your risk for Alzheimer’s disease, study findsNew research published Wednesday found that drinking a shot of espresso could lower a person’s risk for Alzheimer’s disease.
Les mer »
Misdiagnoses disable, kill 800,000 Americans a year, says new studyNew study says 800,000 Americans die or are disabled by misdiagnoses each year — but there are 3 simple questions to ask to lower your risk
Les mer »
A Giant Study Reveals What Happens if You Cram Exercise Into The WeekendExercise is good for your overall health and your heart in particular.
Les mer »